On Nov 06, major Wall Street analysts update their ratings for $Globus Medical (GMED.US)$, with price targets ranging from $85 to $100.
Wells Fargo analyst Vik Chopra maintains with a buy rating, and adjusts the target price from $78 to $88.
Needham analyst David Saxon maintains with a hold rating.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and maintains the target price at $87.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and adjusts the target price from $80 to $92.
Piper Sandler analyst Matthew O'Brien maintains with a buy rating, and adjusts the target price from $80 to $100.
Furthermore, according to the comprehensive report, the opinions of $Globus Medical (GMED.US)$'s main analysts recently are as follows:
Globus Medical is anticipated to return to mid-to-high single-digit sales growth and mid-30's EBITDA margins. The company's earnings outperformance was noted as 'impressive,' driven by robust sales and increasing cost synergies.
Globus Medical has demonstrated consistent performance beyond expectations, particularly in managing the integration of NuVasive more effectively than anticipated, which justifies an improved valuation multiple due to better integration execution and enhanced profitability. Nonetheless, there are challenges ahead, such as realizing cross-selling synergies, which may prove difficult in light of upcoming competition in the spine robot market, potentially complicating the achievement of projected growth rates.
Globus Medical is demonstrating the effectiveness of spine mergers, contrary to common skepticism, as evidenced by their recent third-quarter earnings surpass and raised forecasts. The company's strict financial discipline and operational execution appear to be generating a synergistic effect, which is expected to result in a substantial conversion of free cash flow, potentially fueling share repurchases.
The firm is of the opinion that a strong third-quarter performance, coupled with increased guidance and positive revisions to consensus estimates, should contribute to the stock's appreciation and bolster investor confidence.
Here are the latest investment ratings and price targets for $Globus Medical (GMED.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月6日，多家華爾街大行更新了$Globus Medical (GMED.US)$的評級，目標價介於85美元至100美元。
富國集團分析師Vik Chopra維持買入評級，並將目標價從78美元上調至88美元。
Needham分析師David Saxon維持持有評級。
BTIG分析師Ryan Zimmerman維持買入評級，維持目標價87美元。
加皇資本市場分析師Shagun Singh Chadha維持買入評級，並將目標價從80美元上調至92美元。
派傑投資分析師Matthew O'Brien維持買入評級，並將目標價從80美元上調至100美元。
此外，綜合報道，$Globus Medical (GMED.US)$近期主要分析師觀點如下：
globus medical預計將實現中至高個位數的銷售增長和中30年代的EBITDA利潤率。 公司的收益超預期，憑藉強勁的銷售和成本協同效應的增加而備受稱讚爲「令人印象深刻」
globus medical展示出了超出預期的持續表現，特別是在更有效地管理NuVasive的整合方面比預期更好，這證明了由於更佳的整合執行和增強的盈利能力而應得到改善的估值倍數。 儘管如此，未來仍面臨挑戰，例如實現跨銷售協同效應可能會面臨困難，鑑於脊柱機器人市場即將出現的競爭，這可能會使預期增長率的實現複雜化。
globus medical顯示了脊椎合併的有效性，與普遍懷疑相反，這一點可從他們最近第三季度盈利超過和提高預測中看出。 公司嚴格的財務紀律和運營執行似乎產生了一個協同效應，預計將導致自由現金流的大幅轉換，可能推動股票回購。
公司認爲強勁的第三季度業績，加上增加的指引和對共識估值的積極修訂，應有助於股價的上漲並增強投資者信心。
以下爲今日6位分析師對$Globus Medical (GMED.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
